This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Journal of Cardiothoracic Surgery
MAY 10, 2024
Total anomalous pulmonary venous connection (TAPVC) is a rare congenital heart disease characterized by the inability of all pulmonary veins to connect to the left atrium. Our previous bibliometric article sum.
52 
Dr. Smith's ECG Blog
JUNE 17, 2024
He was started on a heparin drip and CTA of the chest was ordered to rule out pulmonary embolism. This is a case like many others posted (see list below) and the EKG from the patient’s original presentation can be quickly recognized as diagnostic for pulmonary embolism. In fact, Kosuge et al. Accessed May 28, 2024. This is a quiz.
141 
American College of Cardiology
DECEMBER 21, 2023
What are the temporal trends in pulmonary valve replacement (PVR) procedural volume and durability of bioprosthetic pulmonary valves (BPV)?
61 
American College of Cardiology
APRIL 4, 2024
What are the short-term outcomes for patients with native or surgically repaired right ventricular outflow tract (RVOT) undergoing transcatheter pulmonary valve replacement (TPVR) with a self-expanding valve?
60 
American College of Cardiology
JUNE 10, 2024
What is the comparative effectiveness of therapies targeting the different treatment pathways in pulmonary arterial hypertension (PAH)?
53 
American College of Cardiology
OCTOBER 7, 2024
The following are key points to remember from a review comparing international clinical practice guideline recommendations for acute pulmonary embolism (PE):
56 
DAIC
APRIL 18, 2024
Two articles and an accompanying editorial in Heart Rhythm , the official journal of the Heart Rhythm Society, the Cardiac Electrophysiology Society , and the Pediatric & Congenital Electrophysiology Society , published by Elsevier , address the controversy and recommend shortening the blanking period. Lead author Jonathan M.
Open Heart
FEBRUARY 7, 2024
Background Right ventricular (RV) dysfunction is associated with adverse outcomes in patients with pulmonary hypertension (PH). Methods We searched for articles presenting the HR of two-dimensional RVfwLS in PH. Results Twenty articles totalling 2790 subjects were included. HRs were standardised using the within-study SD.
52 
American College of Cardiology
AUGUST 7, 2024
In this week’s View, Dr. Eagle looks at post-capillary pulmonary hypertension in heart failure and the revised European guideline definition. He then explores obesity in adolescents and its impact on our societal health.
61 
The British Journal of Cardiology
JANUARY 16, 2024
Pulmonary hypertension is a rare disease, associated with a significant deterioration in quality of life, usually not curable and with an ominous prognosis. We present the case of a patient diagnosed with precapillary component pulmonary hypertension, with the finding of an arteriovenous fistula at the peripheral level.
52 
American College of Cardiology
JUNE 28, 2024
For the treatment of pulmonary arterial hypertension (PAH), is sildenafil 80 mg TID noninferior to sildenafil 5 mg TID for all-cause mortality?
58 
American College of Cardiology
APRIL 29, 2024
What is the real-world lesion durability of pulmonary vein isolation (PVI) with pulsed-field ablation (PFA) among patients with clinically indicated redo procedures?
56 
American College of Cardiology
JANUARY 23, 2024
The goal of the A DUE trial was to compare the safety and efficacy of macitentan/tadalafil combination therapy versus macitentan and tadalafil monotherapies in patients with pulmonary arterial hypertension (PAH).
53 American College of Cardiology
JUNE 12, 2024
In this week’s View, Dr. Eagle looks at excess apolipoprotein-B and cardiovascular risk, then examines a recent meta-analysis on treating pulmonary arterial hypertension. Finally, Dr. Eagle shares some thoughts on a SMART-C collaborative meta-analysis of sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes.
58 
European Journal of Heart Failure
DECEMBER 13, 2023
ABSTRACT Aim Chronic obstructive pulmonary disease (COPD) is common in heart failure with a mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and is associated with worse outcomes. Methods and results Patients with severe pulmonary disease (including COPD) were excluded from the trial.
American College of Cardiology
DECEMBER 14, 2023
What is the impact on prognosis of the 2022 ESC/ERS pulmonary hypertension (PH) guidelines on the new redefined hemodynamic threshold for the diagnosis of precapillary PH?
49 Circulation
NOVEMBER 24, 2024
Circulation, Volume 150, Issue 22 , Page e467-e467, November 26, 2024.
45 American College of Cardiology
JUNE 28, 2024
™s Cordellaâ„¢ Pulmonary Artery Sensor System for the treatment of patients with NYHA class III heart failure (HF). Food and Drug Administration (FDA) on June 24 gave premarket approval for Endotronix, Inc.’s
45 
American College of Cardiology
MAY 1, 2024
In this week’s View, Dr. Eagle looks at the durability of pulmonary vein isolation using pulsed-field ablation, then examines genetic penetrance of dilated cardiomyopathy in genotype-positive relatives.
Frontiers in Cardiovascular Medicine
MAY 8, 2024
Pulmonary arterial hypertension (PAH) is a chronic and progressive disease that eventually leads to heart failure (HF) and subsequent fatality if left untreated. Right ventricular (RV) function has proven prognostic values in patients with a variety of heart diseases including PAH.
40 Journal of Cardiovascular Pharmacology
MARCH 13, 2024
Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary vascular resistance, imposing overload on the right ventricle (RV) and imbalance of redox state. PAH induction was implemented by a single dose of MCT (60 mg/kg i.p.). Treatment with SFN (2.5 mg/kg/day i.p.)
40 
American College of Cardiology
SEPTEMBER 2, 2024
The goal of the SHAM-PVI trial was to compare the clinical efficacy of cryoballoon pulmonary vein isolation (PVI) to a sham procedure in the treatment of symptomatic atrial fibrillation (AF).
Medical Xpress - Cardiology
DECEMBER 4, 2024
The perspectives and priorities of people living with chronic obstructive pulmonary disease (COPD) should be integrated into the development process of new therapies for COPD, according to a new commentary. The article is published in the Annals of the American Thoracic Society.
40 
Journal of Cardiovascular Pharmacology
JULY 1, 2024
However, whether AMOTL2 is linked to pulmonary arterial hypertension (PAH) has not been addressed. Overexpression of AMOTL2 also led to a noteworthy decrease in vascular wall thickness, pulmonary artery area, and collagen deposition in rats with PAH. This work aimed to investigate the potential role of AMOTL2 in PAH.
40 
International Journal of Cardiovascular Sciences
SEPTEMBER 21, 2023
Access below the articles from the thematic collection on Cardiometablism.
52 
Journal of Cardiothoracic Surgery
FEBRUARY 8, 2024
The decision of whether to perform a large anatomic resection for a lung mass that is not definitely malignant comes often forward in the everyday practice of the thoracic surgeon. The general characteristics.
40 
American College of Cardiology
MAY 3, 2024
Acute pulmonary embolism (PE) is a frequently encountered diagnosis in both the emergency department (ED) and among hospitalized patients, with increasing incidence throughout the U.S.
40 
American College of Cardiology
SEPTEMBER 2, 2024
Compared with a sham procedure, pulmonary vein isolation resulted in a statistically significant and clinically important decrease in atrial fibrillation (AFib) burden at six months, according to results from the SHAM-PVI trial presented at ESC Congress 2024 in London and simultaneously published in JAMA.
40 
American College of Cardiology
OCTOBER 29, 2024
The goal of the trial was to compare the efficacy and safety of large-bore mechanical thrombectomy (LBMT) with catheter-directed thrombolysis (CDT) in the treatment of intermediate-high risk pulmonary embolism (PE).
40 Journal of Cardiovascular Electrophysiology
NOVEMBER 5, 2023
Abstract Introduction Carina breakthrough (CB) at the right pulmonary vein (RPV) can occur after circumferential pulmonary vein isolation (PVI) due to epicardial bridging or transient tissue edema. High-power short-duration (HPSD) ablation may increase the incidence of RPV CB.
40 Journal of Cardiovascular Electrophysiology
JANUARY 11, 2024
In this study, AEPVR (acute epicardial pulmonary vein reconnection) was differentiated in characteristics from endocardial conduction gap in acute PVR (left). We aimed to investigate the prevalence, locations, electrogram characteristics, and ablation parameters related to acute epicardial pulmonary vein reconnection (AEPVR).
40 
Journal of Cardiovascular Electrophysiology
MARCH 3, 2024
Abstract Introduction Through systematic scientific rigor, the CLOSE guided workflow was developed and has been shown to improve pulmonary vein isolation durability. However, this technique was developed at a time when using power-controlled ablation catheters with conventional power ranges was the norm.
40 
Journal of Cardiovascular Pharmacology
OCTOBER 30, 2023
Abstract: Pulmonary artery hypertension (PAH) is characterized by pulmonary arterial endothelial cells (PAECs) dysfunction and pulmonary artery smooth muscle cells (PASMCs) activation. For decades, the therapies for PAH based on stem cells have been shown to be effective.
40 Journal of Cardiovascular Pharmacology
JANUARY 16, 2024
Pulmonary arterial hypertension (PAH) is a persistent condition affecting the pulmonary arteries' endothelium. The present study was designed to investigate the effect of benidipine alone and in combination with bosentan and sildenafil on monocrotaline (MCT)-induced pulmonary hypertension (PH) in a rat model.
40 Journal of Cardiovascular Pharmacology
APRIL 4, 2024
Myocardial infarction (MI) and pulmonary artery hypertension (PAH) are two prevalent cardiovascular diseases. In the PAH model, PTE improved pulmonary artery flow and decreased ROS levels in the lung. PTE also improved cardiac function in infarcted rats and pulmonary artery flow in animals with PAH.
Journal of Cardiovascular Pharmacology
DECEMBER 25, 2023
Shortness of breath and syncope are common symptoms of right ventricular failure caused by pulmonary arterial hypertension (PAH), which is the result of blockage and increased pressure in the pulmonary arteries. Animals were given normal saline or rosmarinic acid (RA) (10, 15, and 30 mg/kg, gavage) for 21 days.
40 
Open Heart
JANUARY 6, 2022
Background The limited availability of balloon sizes for cryoballoon leads to anatomical limitations for pulmonary vein (PV) isolation. Search keywords included ‘atrial fibrillation’, ‘cryoballoon ablation’ and ‘anatomy’ Results Overall, 243 articles were identified.
52 
Journal of Cardiovascular Electrophysiology
NOVEMBER 5, 2024
Abstract Introduction The novel cryoballoon with 28mm or 31mm adjustable diameters, aims to achieve a wide antral pulmonary vein isolation (PVI). We assessed the shapes of the LA and pulmonary veins (PVs) and the distribution of isolated areas (IAs), comparing the results between PAF and non-PAF patients.
40 Journal of Cardiovascular Electrophysiology
MARCH 6, 2024
This novel cryoballoon with adjustable size and low compliance successfully achieves pulmonary vein isolation to treat paroxysmal atrial fibrillation (PAF), providing more options for patients with PAF. This cryoballoon system was proven to be safe and effective for treatment of patients with drug refractory or drug intolerant PAF.
40 
Journal of Cardiovascular Pharmacology
NOVEMBER 11, 2024
Pulmonary arterial hypertension (PAH) is a cardiopulmonary vascular condition with an unclear pathogenesis. Pulmonary arterial hypertension (PAH) is a cardiopulmonary vascular condition with an unclear pathogenesis. Microarray data for PAH and ER stress-related genes were analyzed.
40 
Journal of Cardiovascular Electrophysiology
FEBRUARY 8, 2024
Abstract Introduction Pulsed field ablation (PFA) has emerged as an innovative technique for pulmonary vein isolation (PVI). Typically, a transeptal puncture (TSP) with a standard sheath precedes a switch to the larger diameter sheath in the left atrium.
40 
Journal of Cardiovascular Electrophysiology
DECEMBER 7, 2023
Abstract Introduction Although first-pass isolation (FPI) of the pulmonary vein (PV) has been suggested as a marker for PV isolation (PVI) durability, it has not been confirmed. Non-PV atrial fibrillation (AF) triggers were the main target in patients without PV reconnection in the second ablation procedure, but the outcome was unclear.
Journal of Cardiovascular Electrophysiology
DECEMBER 7, 2023
Abstract Introduction Atrial tachyarrhythmia recurrence during the blanking period (early ATA) after pulmonary vein isolation (PVI) is associated with an increased risk of later recurrence, but its relationship with pulmonary vein reconduction (PVR) is poorly understood.
40
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content